Alexander Perl, MD is a member of the leukemia program in the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor of Medicine at the Perelman School of Medicine. He earned his MD degree from the Mount Sinai School of Medicine and a MS degree in Translational Research from the University of Pennsylvania. Dr. Perl completed post-graduate medical residency training in internal medicine at the University of California, San Francisco and fellowship training in medical oncology at the Johns Hopkins Hospital. He has been a faculty member at the University of Pennsylvania since 2003 where his clinical and research expertise are in molecularly-targeted therapeutics for acute leukemia. In particular, Dr. Perl played a key role in the clinical development of a number of FLT3 inhibitors for AML including serving as lead investigator for the first-in-human and pivotal trials of gilteritinib. Dr. Perl has published over 100 original research articles, invited reviews, commentaries, or book chapters and is a frequent invited speaker internationally on the topic of clinical management of AML in the era of novel therapeutics. He also contributes to US national practice guidelines by serving on the National Comprehensive Cancer Center Network (NCCN) AML panel. Dr. Perl’s laboratory efforts have focused upon late pre-clinical drug assessment, pharmacodynamic analysis of targeted agents from trials, and analysis of resistance mechanisms to targeted therapy.